StockNews.AI
BFRI
StockNews.AI
161 days

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

1. BFRI will report financial results on March 21, 2025. 2. Results will be announced before market opens, followed by a conference call. 3. BFRI focuses on dermatological treatments using Ameluz® and RhodoLED® lamps. 4. They are expanding trials for additional dermatological conditions. 5. Continued development could influence BFRI's market positioning and stock price.

Earnings
+5.07%Current Return
VS
+0.32%S&P 500
$0.875603/11 10:04 AM EDTEvent Start
$0.9203/12 04:24 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could indicate business growth. Historically, positive earnings reports lead to stock appreciation.

How important is it?

Earnings releases directly affect investor sentiment and stock valuation. Anticipation builds around product potential and market response.

Why Short Term?

Immediate reactions expected post-earnings announcement. Short-term performance often swayed by quarterly results.

Related Companies

AMGNMRKVRTX
WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time. Conference Call and Webcast Information About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X. Contacts:Investor RelationsAndrew Barwicki1-516-662-9461ir@bfri.com SOURCE: Biofrontera Inc.

Related News